Telomir Pharmaceuticals Inc(TELO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:21 PM ET (Korea 11/6 06:21)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.91 | Insider Own | - | Shs Outstand | 73.6M | Perf Week | -19.09% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 73.6M | Perf Month | -30.35% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.03 | Inst Own | 4% | Short Float | 1.05% | Perf Quarter | -32.75% |
| Income | -0.05B | P/S | - | EPS this Y | - | Inst Trans | 5.73% | Short Ratio | 8.83 | Perf Half Y | -40.9% |
| Sales | 0.00B | P/B | 10.66 | EPS next 5Y | 32.79% | ROA | -189.68% | Short Interest | 0.77M | Perf YTD | -41.35% |
| Book/sh | 0.07 | P/C | 11.12 | EPS past 3/5Y | -125.22% -189.25% | ROE | -213.1% | 52W High | -50.63% ($1.58) | Perf Year | -43.88% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | -116.74% | 52W Low | -1.32% ($0.79) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -67.73% | Gross Margin | - | Volatility(W/M) | 9.85% 7.07% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.14 | EPS Q/Q | -365.54% | Profit Margin | - | RSI (14) | 18.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.14 | Sales Q/Q | - | SMA20 | -21.69% ($1) | Beta | -0.19 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/09/02 | SMA50 | -29.39% ($1.1) | Rel Volume | 1.9 | Prev Close | $0.88 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -35.7% ($1.21) | Avg Volume(3M) | 0.09M | Price | $0.78 |
| IPO | 2024/2/9 | Option/Short | No/Yes | Trades | 316 | Volume | 165,508 | Change | -10.85% |
🧬 A US-based, pre-clinical stage biotech developing oral small-molecule candidates targeting aging and age-related diseases. The company highlights mechanisms that act on metal ion regulation, oxidative stress, mitochondrial function, and telomere integrity, and operates with a pipeline-focused structure, with no commercial products or revenue yet.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded more than usual. That is 190% of its average volume.
TELO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.8% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #395 of 597 in the industry
Based on market cap of $57M.
GOSS#394 Gossamer Bio Inc $58M PER - TELO#395 Telomir Pharmaceuticals Inc $57M PER - 
ONCY#396 Oncolytics Biotech Inc $57M PER - 
XBIT#397 XBiotech Inc $57M PER - 
XLO#398 Xilio Therapeutics Inc $57M PER - 
FAQ
What kind of company is TELO?
TELO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TELO?
The market cap of TELO is approximately $57M, ranking 4,758 within its sector.
What is the 52-week high and low for TELO?
TELO has recorded a 52-week high of $1.58 and a low of $0.79.
